Showing results (221-230 of 1,146) with videos related to
Sort By:
Pageof 115
Methods in Molecular Medicine|March 11, 2011
Construction of p450-expressing tumor cell lines using retrovirusesJ E Hecht, Y Jounaidi, D J WaxmanMolecular and Cellular Biology|December 14, 2011
Dynamic, sex-differential STAT5 and BCL6 binding to sex-biased, growth hormone-regulated genes in adult mouse liverYijing Zhang, Ekaterina V Laz, David J WaxmanMolecular Endocrinology (Baltimore, Md.)|May 25, 2004
Sexually dimorphic P450 gene expression in liver-specific hepatocyte nuclear factor 4alpha-deficient miceChristopher A Wiwi, Minita Gupte, David J WaxmanCancer Gene Therapy|November 18, 2008
Potentiation of methoxymorpholinyl doxorubicin antitumor activity by P450 3A4 gene transferH Lu, C-S Chen, D J WaxmanHuman Gene Therapy|September 6, 2008
Human telomerase reverse transcriptase promoter-driven oncolytic adenovirus with E1B-19 kDa and E1B-55 kDa gene deletionsJoshua C Doloff, David J Waxman, Youssef JounaidiCurrent Cancer Drug Targets|May 17, 2007
Conditionally replicating adenoviruses for cancer treatmentYoussef Jounaidi, Joshua C Doloff, David J WaxmanBritish Journal of Urology|May 1, 1997
British urological surgery practice: 1. Prostate cancerP Savage, C Bates, P Abel, et al.Biochemistry|May 11, 1982
Studies on the chirality of sulfoxidation catalyzed by bacterial flavoenzyme cyclohexanone monooxygenase and hog liver flavin adenine dinucleotide containing monooxygenaseD R Light, D J Waxman, C WalshBiochemistry|May 11, 1982
Chiral sulfoxidations catalyzed by rat liver cytochromes P-450D J Waxman, D R Light, C WalshCancer Gene Therapy|September 25, 2010
Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERTJ C Doloff, Y Jounaidi, D J WaxmanPageof 115